Cholangiocarcinoma Clinical Trial
Official title:
Cytological Evaluation of Biliary Epithelium After Previous Endoscopic Sphincterotomy for Benign Disease
PROTOCOL
Introduction: The introduction of endoscopic retrograde cholangio-pancreatography (ERCP) and
endoscopic sphincterotomy (ES) in 1974 has dramatically changed the treatment of biliary and
pancreatic diseases. ES permits transection of Oddi's sphincter, allowing the endoscopist to
remove stones and place stents.
The main indications for ERCP are: 1. Removal of common bile duct stones 2. Dilation of
benign biliary ducts strictures 3. Stent placement in patients with malignancy 4. Acute
biliary pancreatitis 5. Removal of stones and dilation of strictures of the main pancreatic
duct in patients with chronic pancreatitis and 6. Treatment of biliary fistulae after
surgical operations .
Complications of ES can be described as early (within one month after ES) and late. Early
complications have approximately a 10% incidence and include: 1.acute pancreatitis (5,4%)
2.bleeding (2%) 3.acute cholangitis (1%) 4.acute cholecystitis (0,5%) 5. Perforation and
others (1,1%). Late complications are mainly the recurrence of choledocholithiasis (2,5%),
narrowing of the previous ES and recurrent acute cholangitis. Furthermore, there is a debate
in the literature about late development of cholangiocarcinoma.
Carcinogenesis after surgical sphincteroplasty and biliary-enteric anastomosis has been
described. Previous studies have shown late development of cholangiocarcinoma after
transduodenal sphincteroplasty and biliary-enteric anastomosis for benign disease. The
incidence is up to 7% in a twenty-year follow up, while in the general population is
approximately 1/ 100.000 . In addition, Tocchi et al showed that the rate of
cholangiocarcinoma after transduodenal sphincteroplasty and choledochoduodenal anastomosis
is up to 5-7% and after other choledochi-enteric anastomoses approximately 1,9%. It seems
that the ablation of sphincter function causes prolonged pancreatobiliary and duodenobiliary
reflux. Proteolytic pancreatic enzymes are activated and bacterial intestinal flora
colonizes the biliary epithelium, causing recurrent inflammation. Chronic inflammatory
irritation may lead to hyperplasia, dysplasia and atypia of epithelium, ultimately inducing
carcinogenesis.
Eleftheriadis et al, studied changes of the biliary epithelium in patients who underwent
choledochi-duodenal anastomosis for benign disease, and hyperplasia of the biliary
epithelium was demonstrated. The same results and atypia of biliary epithelium were reported
by Kurumado et al, in mice models with choledochi-duodenal anastomosis. Anomalous
pancreatobiliary junction and choledochal cysts produce the same histologic alterations of
the biliary epithelium.
These facts raise a great amount of concern about late development of cancer after ES.
Bergman et al in a small trial argues that after ES, the function of the biliary sphincter
is permanently lost. On the other hand, Sugiyama et al demonstrated the reduction of
pancreatobiliary reflux 1 year after ES. In addition, large population-based studies have
shown no causal association between ES and cholangiocarcinoma, but with enough limitations
in study design. In conclusion, the long term cytologic changes of the biliary epithelium
after ES for benign disease are not well known.
During ERCP, brush cytology can be performed to evaluate bile duct strictures. The use of
endoscopic brushing after ES has no reported complications .
Objective: To evaluate cytologic alterations of the biliary epithelium after previous
endoscopic sphincterotomy for benign disease.
Informed consent will be obtained from all patients. ERCP will be conducted at the
Endoscopic Unit of Aretaieion University Hospital and Tzaneio General Hospital, Athens,
Greece. Pethidine, midazolam or propofol will be used for patient sedation. ERCP will be
conducted with the use of a side viewing endoscope. After catheterization of the common bile
duct through the previous sphincterotomy, cellular material will be obtained with the use of
an endoscopic brush from the bile ducts. With the same way, brush cytology will be performed
in the control group after performing ES.
Material obtained from each patient will be smeared on five glass slides. Four slides will
be fixed with ethanol solution 95% and the fifth will be air dried. The brush will be fixed
in suitable liquid for performing liquid phase cytology. Immunocytology with
immunofluorescence p-53 antibody will be performed in samples with hyperplasia, dysplasia or
atypia. The cytology department of Tzaneio Hospital will conduct examination and evaluation
of all samples.
Samples based on their morphological characteristics will be classified in five categories:
a. inadequate sample (very small cell number, presence of blood, inadequate fixation) b.
negative for malignancy (adequate cell number with benign morphologic characteristics) c.
reactive with or without atypia (cells with reactive/proliferative or inflammatory
characteristics. Malignancy is rare but cannot be excluded) d. suspicious for malignancy e.
positive for malignancy [21,22].
Examination and evaluation of the specimens will be done by two specialized cytologists,
separately, in order to achieve more objective results.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05179486 -
Molecular Epidemiology of Biliary Tree Cancers
|
||
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Terminated |
NCT04304781 -
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
|
Phase 1 | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT01912053 -
Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT01439698 -
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
|
N/A | |
Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
Completed |
NCT01206049 -
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
|
Phase 2 | |
Recruiting |
NCT00973713 -
Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
|
Phase 2 | |
Terminated |
NCT00975039 -
Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT00779454 -
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
Recruiting |
NCT04340986 -
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
|
||
Active, not recruiting |
NCT04526106 -
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03603834 -
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 |